Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with Chemotherapy for Relapsed T-ALL/T-LLy (ENCERT)
NCT03328104Phase 1Completed
- Sponsor
- Emory University
- Start
- Jul 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Emory University. Primary endpoint: Maximum Tolerated Dose. Started Jul 2018; status: completed.
02
Drugs
everolimus
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT03328104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328104.